Comparison of intrapulmonary percussive ventilation and chest physiotherapy: A pilot study in patients with cystic fibrosis

JoAnne E Natale, J. Pfeifle, D. N. Hommick

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Study objective: To compare the intrapulmonary percussive ventilator (IPV) to chest physiotherapy (P and PD) with respect to acute changes in (1) pulmonary function and (2) sputum physical properties in patients with cystic fibrosis (CF). Design: Randomized crossover. Setting: Community-based CF referral center. Participants: Nine nonhospitalized persons (range, 7 to 40 years; median, 12.4 years) with moderate to excellent Shwachman scores. Interventions: Three treatment regimens: (1) 2.5 mg albuterol delivered via IPV (internal percussive component activated); (2) 2.5 mg albuterol delivered via IPV (internal percussive component inactivated), followed by P and PD; and (3) 2.5 mg albuterol delivered via updraft nebulizer, followed by P and PD. Measurements and results: Outcome measures included pulmonary function testing (PFTs) and quantitative and qualitative sputum analysis. Among the three treatment groups, there were no significant differences in the change in predicted PFTs 1 h or 4 h after treatment, nor in the volume of sputum expectorated in the first 4 or in the subsequent 20 h. Among patients receiving IPV, more serious disease was associated with greater improvement in FEF25-75 1 h after treatment, but these differences disappeared by 4 h. There were no meaningful differences in viscoelastic characteristics of sputum expectorated after each treatments. Participants reported general satisfaction with no adverse effects while using IPV. Conclusions: This initial pilot study suggests (1) stable patients with CF tolerated one treatment of IPV without adverse sequelae, and (2) IPV was as effective as standard aerosol and P and PD in improving short-term PFT results and enhancing sputum expectoration.

Original languageEnglish (US)
Pages (from-to)1789-1793
Number of pages5
JournalChest
Volume105
Issue number6
StatePublished - 1994
Externally publishedYes

Fingerprint

Mechanical Ventilators
Cystic Fibrosis
Ventilation
Thorax
Sputum
Albuterol
Lung
Therapeutics
Nebulizers and Vaporizers
Aerosols
Cross-Over Studies
Referral and Consultation
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Comparison of intrapulmonary percussive ventilation and chest physiotherapy : A pilot study in patients with cystic fibrosis. / Natale, JoAnne E; Pfeifle, J.; Hommick, D. N.

In: Chest, Vol. 105, No. 6, 1994, p. 1789-1793.

Research output: Contribution to journalArticle

@article{fcc9547b148c445d9a0c81a25b63875f,
title = "Comparison of intrapulmonary percussive ventilation and chest physiotherapy: A pilot study in patients with cystic fibrosis",
abstract = "Study objective: To compare the intrapulmonary percussive ventilator (IPV) to chest physiotherapy (P and PD) with respect to acute changes in (1) pulmonary function and (2) sputum physical properties in patients with cystic fibrosis (CF). Design: Randomized crossover. Setting: Community-based CF referral center. Participants: Nine nonhospitalized persons (range, 7 to 40 years; median, 12.4 years) with moderate to excellent Shwachman scores. Interventions: Three treatment regimens: (1) 2.5 mg albuterol delivered via IPV (internal percussive component activated); (2) 2.5 mg albuterol delivered via IPV (internal percussive component inactivated), followed by P and PD; and (3) 2.5 mg albuterol delivered via updraft nebulizer, followed by P and PD. Measurements and results: Outcome measures included pulmonary function testing (PFTs) and quantitative and qualitative sputum analysis. Among the three treatment groups, there were no significant differences in the change in predicted PFTs 1 h or 4 h after treatment, nor in the volume of sputum expectorated in the first 4 or in the subsequent 20 h. Among patients receiving IPV, more serious disease was associated with greater improvement in FEF25-75 1 h after treatment, but these differences disappeared by 4 h. There were no meaningful differences in viscoelastic characteristics of sputum expectorated after each treatments. Participants reported general satisfaction with no adverse effects while using IPV. Conclusions: This initial pilot study suggests (1) stable patients with CF tolerated one treatment of IPV without adverse sequelae, and (2) IPV was as effective as standard aerosol and P and PD in improving short-term PFT results and enhancing sputum expectoration.",
author = "Natale, {JoAnne E} and J. Pfeifle and Hommick, {D. N.}",
year = "1994",
language = "English (US)",
volume = "105",
pages = "1789--1793",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "6",

}

TY - JOUR

T1 - Comparison of intrapulmonary percussive ventilation and chest physiotherapy

T2 - A pilot study in patients with cystic fibrosis

AU - Natale, JoAnne E

AU - Pfeifle, J.

AU - Hommick, D. N.

PY - 1994

Y1 - 1994

N2 - Study objective: To compare the intrapulmonary percussive ventilator (IPV) to chest physiotherapy (P and PD) with respect to acute changes in (1) pulmonary function and (2) sputum physical properties in patients with cystic fibrosis (CF). Design: Randomized crossover. Setting: Community-based CF referral center. Participants: Nine nonhospitalized persons (range, 7 to 40 years; median, 12.4 years) with moderate to excellent Shwachman scores. Interventions: Three treatment regimens: (1) 2.5 mg albuterol delivered via IPV (internal percussive component activated); (2) 2.5 mg albuterol delivered via IPV (internal percussive component inactivated), followed by P and PD; and (3) 2.5 mg albuterol delivered via updraft nebulizer, followed by P and PD. Measurements and results: Outcome measures included pulmonary function testing (PFTs) and quantitative and qualitative sputum analysis. Among the three treatment groups, there were no significant differences in the change in predicted PFTs 1 h or 4 h after treatment, nor in the volume of sputum expectorated in the first 4 or in the subsequent 20 h. Among patients receiving IPV, more serious disease was associated with greater improvement in FEF25-75 1 h after treatment, but these differences disappeared by 4 h. There were no meaningful differences in viscoelastic characteristics of sputum expectorated after each treatments. Participants reported general satisfaction with no adverse effects while using IPV. Conclusions: This initial pilot study suggests (1) stable patients with CF tolerated one treatment of IPV without adverse sequelae, and (2) IPV was as effective as standard aerosol and P and PD in improving short-term PFT results and enhancing sputum expectoration.

AB - Study objective: To compare the intrapulmonary percussive ventilator (IPV) to chest physiotherapy (P and PD) with respect to acute changes in (1) pulmonary function and (2) sputum physical properties in patients with cystic fibrosis (CF). Design: Randomized crossover. Setting: Community-based CF referral center. Participants: Nine nonhospitalized persons (range, 7 to 40 years; median, 12.4 years) with moderate to excellent Shwachman scores. Interventions: Three treatment regimens: (1) 2.5 mg albuterol delivered via IPV (internal percussive component activated); (2) 2.5 mg albuterol delivered via IPV (internal percussive component inactivated), followed by P and PD; and (3) 2.5 mg albuterol delivered via updraft nebulizer, followed by P and PD. Measurements and results: Outcome measures included pulmonary function testing (PFTs) and quantitative and qualitative sputum analysis. Among the three treatment groups, there were no significant differences in the change in predicted PFTs 1 h or 4 h after treatment, nor in the volume of sputum expectorated in the first 4 or in the subsequent 20 h. Among patients receiving IPV, more serious disease was associated with greater improvement in FEF25-75 1 h after treatment, but these differences disappeared by 4 h. There were no meaningful differences in viscoelastic characteristics of sputum expectorated after each treatments. Participants reported general satisfaction with no adverse effects while using IPV. Conclusions: This initial pilot study suggests (1) stable patients with CF tolerated one treatment of IPV without adverse sequelae, and (2) IPV was as effective as standard aerosol and P and PD in improving short-term PFT results and enhancing sputum expectoration.

UR - http://www.scopus.com/inward/record.url?scp=0028231849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028231849&partnerID=8YFLogxK

M3 - Article

C2 - 8205878

AN - SCOPUS:0028231849

VL - 105

SP - 1789

EP - 1793

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6

ER -